CV Sciences Inc. (CVSI)
OTCQB OTCQB Primary Summary
CVSI Chart
CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3
SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 23, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today applauds Texas Governor Greg Abbott for vetoing Senate Bill 3, which would have created an effective ban on the sale of consumable hemp products across the state of Texas. The proposed legislation posed a direct threat to Texas's robust hemp industry, which supports thousands of jobs and provides effective wellness products for consumers throughout the state.
CV Sciences, Inc. (CVSI) Q1 2025 Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q1 2025 - Earnings Conference Call May 14, 2025 4:00 PM ET Company Participants Brendan Hawkins - IR Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Operator Greetings, and welcome to CV Sciences' First Quarter 2025 Earnings Conference Call. At this time, participants are in a listen only mode.
CV Sciences, Inc. to Announce First Quarter 2025 Results on May 14, 2025
SAN DIEGO, CA / ACCESS Newswire / May 9, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2025, after the stock market closes on Wednesday, May 14, 2025. The Company will hold a conference call with the investment community at 1:00 p.m.
CV Sciences Inc. Dividends
CV Sciences Inc. Earnings
| 18 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 18 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
CV Sciences Inc. (CVSI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has CV Sciences Inc. ever had a stock split?
CV Sciences Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Joseph D. Dowling CEO | OTCQB Exchange | US1266541028 ISIN |
| United States Country | 42 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CV Sciences, Inc., established in San Diego, California, since its inception in 2010, stands as a significant player in the North American market for herbal supplements and hemp-based cannabidiol (CBD) products. Initially known as CannaVest Corp., the company underwent a name change to CV Sciences, Inc. in January 2016, reflecting its broader commitment to scientific innovation within the CBD industry. The company’s operations encompass the development, manufacturing, marketing, and sale of a variety of CBD-based products and it is also pioneering cannabinoids for potential medical use. It caters to various sectors of the health care market including nutraceuticals, beauty care, specialty foods, and pet products, distributing its offerings through a spectrum of channels including its own websites, select distributors, brick-and-mortar retailers, and certain e-tailers.
Products and Services
- PlusCBD: A flagship product line from CV Sciences that offers an extensive range of CBD-based health and wellness supplements. These products are designed to support overall well-being.
- ProCBD: Catered towards those seeking enhanced benefits from their CBD use, ProCBD products are formulated to target specific wellness goals and concerns, offering a potent alternative within the CBD market.
- HappyLane: This range focuses on delivering 0% THC CBD products, ensuring consumers can enjoy the benefits of CBD without the psychoactive effects of THC. HappyLane is marketed towards individuals conscious about THC intake but eager to explore CBD’s potential.
- PlusCBD Pet: Recognizing the growing demand for pet wellness solutions, CV Sciences extends its CBD expertise to our furry friends. PlusCBD Pet products are designed to offer pets the same quality of CBD support that humans enjoy.
- CVSI-007: Beyond their consumer products, CV Sciences is invested in developing cannabinoids for therapeutic purposes. CVSI-007 is one such endeavor, combining CBD and nicotine in an innovative formulation intended to treat smokeless tobacco use and addiction, marking the company’s foray into addressing global health challenges through cannabinoid solutions.
Contact Information
